FR3061305B1 - Methode de diagnostic des qualites esthetiques de la peau - Google Patents
Methode de diagnostic des qualites esthetiques de la peau Download PDFInfo
- Publication number
- FR3061305B1 FR3061305B1 FR1663364A FR1663364A FR3061305B1 FR 3061305 B1 FR3061305 B1 FR 3061305B1 FR 1663364 A FR1663364 A FR 1663364A FR 1663364 A FR1663364 A FR 1663364A FR 3061305 B1 FR3061305 B1 FR 3061305B1
- Authority
- FR
- France
- Prior art keywords
- skin
- diagnosing
- aesthetic qualities
- relates
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title abstract 4
- 230000015556 catabolic process Effects 0.000 abstract 2
- 238000006731 degradation reaction Methods 0.000 abstract 2
- 102100037009 Filaggrin-2 Human genes 0.000 abstract 1
- 101000878281 Homo sapiens Filaggrin-2 Proteins 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000002537 cosmetic Substances 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6881—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from skin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/44—Detecting, measuring or recording for evaluating the integumentary system, e.g. skin, hair or nails
- A61B5/441—Skin evaluation, e.g. for skin disorder diagnosis
- A61B5/442—Evaluating skin mechanical properties, e.g. elasticity, hardness, texture, wrinkle assessment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/148—Screening for cosmetic compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/20—Dermatological disorders
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Analytical Chemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Organic Chemistry (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Cosmetics (AREA)
Abstract
La présente invention concerne une méthode de diagnostic d'une dégradation des qualités esthétiques de la peau, basée sur mesure du niveau d'expression du gène codant la FLG2. La présente invention porte également sur une méthode de traitement cosmétique de la peau. La présente invention concerne également une méthode d'identification de composé de réduction et/ou le ralentissement de la dégradation de la qualité esthétique de la peau ainsi qu'un kit.
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1663364A FR3061305B1 (fr) | 2016-12-23 | 2016-12-23 | Methode de diagnostic des qualites esthetiques de la peau |
JP2019534129A JP6949964B2 (ja) | 2016-12-23 | 2017-12-22 | 皮膚の審美性の診断方法 |
PCT/EP2017/084547 WO2018115517A1 (fr) | 2016-12-23 | 2017-12-22 | Procédé de diagnostic des qualités esthétiques de la peau |
US16/468,073 US20200072851A1 (en) | 2016-12-23 | 2017-12-22 | Method of diagnosis of the aesthetic qualities of the skin |
EP17832238.4A EP3559671B1 (fr) | 2016-12-23 | 2017-12-22 | Procédé de diagnostic des qualités esthétiques de la peau |
JP2021110021A JP2021166536A (ja) | 2016-12-23 | 2021-07-01 | 皮膚の審美性の診断方法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1663364 | 2016-12-23 | ||
FR1663364A FR3061305B1 (fr) | 2016-12-23 | 2016-12-23 | Methode de diagnostic des qualites esthetiques de la peau |
Publications (2)
Publication Number | Publication Date |
---|---|
FR3061305A1 FR3061305A1 (fr) | 2018-06-29 |
FR3061305B1 true FR3061305B1 (fr) | 2021-02-12 |
Family
ID=58779114
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FR1663364A Active FR3061305B1 (fr) | 2016-12-23 | 2016-12-23 | Methode de diagnostic des qualites esthetiques de la peau |
Country Status (5)
Country | Link |
---|---|
US (1) | US20200072851A1 (fr) |
EP (1) | EP3559671B1 (fr) |
JP (2) | JP6949964B2 (fr) |
FR (1) | FR3061305B1 (fr) |
WO (1) | WO2018115517A1 (fr) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR3061305B1 (fr) * | 2016-12-23 | 2021-02-12 | Oreal | Methode de diagnostic des qualites esthetiques de la peau |
US11127176B2 (en) * | 2019-01-31 | 2021-09-21 | L'oreal | Systems and methods for visualizing future skin trends based on biomarker analysis |
US11501356B2 (en) | 2019-07-31 | 2022-11-15 | L'oreal | Systems and methods for generating personalized skincare formulations based on biomarker analysis |
US11741523B2 (en) | 2019-07-31 | 2023-08-29 | L'oreal | Personalized skincare recommendations based on biomarker analysis |
FR3100451B1 (fr) * | 2019-09-05 | 2021-09-17 | Oreal | Méthode de diagnostic de peaux sèches |
FR3117599A1 (fr) * | 2020-12-16 | 2022-06-17 | L'oreal | Méthode de pronostic et/ou de diagnostic d’un état pelliculaire du cuir chevelu |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2940976B1 (fr) * | 2009-01-13 | 2017-11-03 | Oreal | Utilisation a des fins de criblage d'actifs anti-ages de formes solubles de la proteine de type desmogleine i |
JP2011085491A (ja) * | 2009-10-15 | 2011-04-28 | Iwate Univ | カスパーゼの分析方法 |
KR100961874B1 (ko) | 2010-04-05 | 2010-06-09 | 주식회사 나노엔텍 | 외부동력 없이 유체가 이동하는 유체분석용 칩 |
KR101618950B1 (ko) * | 2013-04-12 | 2016-05-09 | 동국대학교 산학협력단 | 피부 자극 물질 스크리닝용 조성물 및 이를 이용한 피부 자극 물질의 스크리닝 방법 |
JP6199592B2 (ja) * | 2013-04-15 | 2017-09-20 | 株式会社 資生堂 | 分析方法 |
KR101507234B1 (ko) | 2013-07-17 | 2015-03-31 | 로레알 | 생분자 추출기 및 생분자 추출방법 |
CA2940585C (fr) * | 2014-04-15 | 2023-08-08 | Helmholtz Zentrum Munchen - Deutsches Forschungszentrum Fur Gesundheit Und Umwelt (Gmbh) | Diagnostic differentiel de l'eczema et du psoriasis |
FR3061305B1 (fr) * | 2016-12-23 | 2021-02-12 | Oreal | Methode de diagnostic des qualites esthetiques de la peau |
-
2016
- 2016-12-23 FR FR1663364A patent/FR3061305B1/fr active Active
-
2017
- 2017-12-22 US US16/468,073 patent/US20200072851A1/en active Pending
- 2017-12-22 JP JP2019534129A patent/JP6949964B2/ja active Active
- 2017-12-22 EP EP17832238.4A patent/EP3559671B1/fr active Active
- 2017-12-22 WO PCT/EP2017/084547 patent/WO2018115517A1/fr unknown
-
2021
- 2021-07-01 JP JP2021110021A patent/JP2021166536A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3559671B1 (fr) | 2024-02-07 |
US20200072851A1 (en) | 2020-03-05 |
JP6949964B2 (ja) | 2021-10-13 |
FR3061305A1 (fr) | 2018-06-29 |
JP2020501587A (ja) | 2020-01-23 |
EP3559671C0 (fr) | 2024-02-07 |
EP3559671A1 (fr) | 2019-10-30 |
JP2021166536A (ja) | 2021-10-21 |
WO2018115517A1 (fr) | 2018-06-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FR3061305B1 (fr) | Methode de diagnostic des qualites esthetiques de la peau | |
MX2018008421A (es) | Métodos para tratar cáncer y el uso de biomarcadores como predictor de sensibilidad clínica a terapias. | |
EA201890724A1 (ru) | Способы диагностики и оценки неалкогольного стеатогепатита | |
MX2017008904A (es) | Biomarcadores basados en sangre para diagnosticar enfermedad de arteria coronaria ateroesclerotica. | |
MX2020001193A (es) | Metodos para determinar dipeptidil peptidasa 3 y metodos terapeuticos. | |
MX2016012133A (es) | Determinacion de un indicador de riesgo de salud. | |
EA201891539A1 (ru) | Соединения, ингибирующие металлоферменты | |
MX341840B (es) | Biomarcadores de microarn indicativos de la enfermedad de alzheimer. | |
WO2015094995A3 (fr) | Biomarqueurs de signature génique de réponse tumorale à des antagonistes de pd-1 | |
NZ729773A (en) | Biomarkers for disease progression in melanoma | |
EA201492284A1 (ru) | Применение маркеров в диагностике и лечении рака предстательной железы | |
EP4321866A3 (fr) | Gdf-15 utilisé comme marqueur diagnostique pour prédire le résultat clinique d'un traitement avec des bloqueurs de points de contrôle immunitaires | |
MA35456B1 (fr) | Procède de traitement fongicide et/ou bactéricide de souches résistantes au moyen d'huile(s) essentielle(s) | |
EA201792447A1 (ru) | Способы и композиции для диагностики и лечения заболеваний у пациентов, имеющих повышенные уровни cxcl9 и других биомаркеров | |
MX2017006242A (es) | Determinacion de niveles de glicosaminoglicanos mediante espectrometria de masas. | |
EA201790549A1 (ru) | Предиктивные и прогностические биомаркеры, связанные с антиангиогенной терапией злокачественной опухоли | |
WO2015168602A3 (fr) | Procédés et compositions pour le diagnostic et le traitement de la maladie de kawasaki | |
WO2017066796A3 (fr) | Modulateurs de maladies impliquant des télomères | |
WO2012167086A3 (fr) | Méthodes de diagnostic et de traitement d'une sclérose latérale amyotrophique | |
BR112021017661A2 (pt) | Uso de compostos 8,9-di-hidrocanabidiol | |
WO2021067850A3 (fr) | Méthodes de détection d'arncirc | |
MX2022010954A (es) | Dispositivo para la deteccion de proteinas mal plegadas y metodos de uso del mismo. | |
MX2022006073A (es) | Metodos para utilizar anticuerpos anti-trem2. | |
WO2015166353A3 (fr) | Détection précoce de pré-éclampsie | |
WO2009091230A3 (fr) | Marqueur protéique pour la surveillance, le diagnostic et le dépistage du cancer du sein, et méthode de surveillance, de diagnostic et de dépistage de cancer du sein faisant appel audit marqueur |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PLFP | Fee payment |
Year of fee payment: 2 |
|
PLSC | Publication of the preliminary search report |
Effective date: 20180629 |
|
PLFP | Fee payment |
Year of fee payment: 4 |
|
PLFP | Fee payment |
Year of fee payment: 5 |
|
PLFP | Fee payment |
Year of fee payment: 6 |
|
PLFP | Fee payment |
Year of fee payment: 7 |
|
PLFP | Fee payment |
Year of fee payment: 8 |